Found 121 cases where Vaccine is COVID19 and Manufacturer is PFIZER/BIONTECH and Symptom is Anti-neutrophil cytoplasmic antibody positive vasculitis

Administered by: Private       Purchased by: ?
Symptoms: Anti-neutrophil cytoplasmic antibody positive vasculitis, Biopsy kidney, Blood creatinine increased, Blood urea increased, Cerebrovascular accident, Cough, Dialysis, Magnetic resonance imaging head, Vomiting
SMQs:, Rhabdomyolysis/myopathy (broad), Acute renal failure (narrow), Anaphylactic reaction (broad), Acute pancreatitis (broad), Ischaemic central nervous system vascular conditions (narrow), Haemorrhagic central nervous system vascular conditions (narrow), Retroperitoneal fibrosis (broad), Embolic and thrombotic events, vessel type unspecified and mixed arterial and venous (narrow), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Vasculitis (narrow), Chronic kidney disease (narrow), Hypersensitivity (narrow), Tumour lysis syndrome (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? Yes
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? Yes, 10 days
Extended hospital stay? No
Previous Vaccinations:
Other Medications: atorvostatin, metoprolol, lisinopril, protonix, aspirin
Current Illness:
Preexisting Conditions: hypertension, high cholesterol, hx MI
Allergies: none
Diagnostic Lab Data: 4/15/2021 Renal biopsy, 4/22/2021 MRI brain
CDC Split Type:

Write-up: Patient with coughing and vomiting starting on 4/10/2021. Patient presents to ER for symptoms and found with elevated BUN/creat. During hospitalization he was dx with C-ANCA vasculitis. Patient with worsening symptoms leading to stroke and need for dialysis.

Administered by: Unknown       Purchased by: ?
Symptoms: Anti-neutrophil cytoplasmic antibody positive vasculitis, Vasculitis
SMQs:, Vasculitis (narrow), Hypersensitivity (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Vasculitis
Allergies:
Diagnostic Lab Data:
CDC Split Type: USPFIZER INC2021486811

Write-up: ANCA Positive Vasculitis; adverse event of vasculitis; This is a spontaneous report from a contactable consumer reported for a male patient received from a Pfizer sponsor program. A male patient of an unspecified age received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Batch/Lot number and Expiration date: unknown), via an unspecified route of administration on an unspecified date, as single dose for covid-19 immunisation. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Batch/Lot number: unknown), via an unspecified route of administration on an unspecified date, as single dose for covid-19 immunisation. Medical history included vasculitis. The patient concomitant medications were not reported. On an unspecified date, following second dose of vaccination, the patient experienced adverse event of vasculitis and, ANCA positive vasculitis (anti-neutrophil cytoplasmic antibody positive vasculitis). It was reported that the patient had ANCA Positive Vasculitis and ended up getting a recurrence of it after getting the vaccine and they were not sure if it was related or not. The reporter mentioned that she was calling to see if there have been any other examples of this happening. The outcome of the events was unknown. Information about lot/batch number can be obtained. Additional information has been requested.

Administered by: Unknown       Purchased by: ?
Symptoms: Anti-neutrophil cytoplasmic antibody positive vasculitis, Biopsy kidney abnormal, Blood test abnormal, Chemotherapy, Death, Dysphagia, Dysphonia, Fatigue, Intensive care
SMQs:, Anticholinergic syndrome (broad), Malignancy related therapeutic and diagnostic procedures (narrow), Parkinson-like events (broad), Oropharyngeal conditions (excl neoplasms, infections and allergies) (narrow), Guillain-Barre syndrome (broad), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (broad), Vasculitis (narrow), Chronic kidney disease (broad), Hypersensitivity (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2021-06-16
   Days after onset: 42
Permanent Disability? No
Recovered? No
Office Visit? Yes
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? Yes, 21 days
Extended hospital stay? No
Previous Vaccinations:
Other Medications: Losartan Potassium Hydrochlorothiazide Levothyroxine Feosol Lantanaprost Bayer low dose aspirin Anastrozole
Current Illness:
Preexisting Conditions: 5 year breast cancer survivor Mini-stroke 05/23/2020 Another mini-stroke 04/2021, exact date uncertain
Allergies: None
Diagnostic Lab Data:
CDC Split Type:

Write-up: 2 months after last dose, a routine bloodwork revealed high kidney numbers. Voice became hoarse and difficulty in swallowing ease was noted. Repeat blood work confirmed kidney numbers still high after hydration, IV fluids given at home. Fatigue increased and I took my mother to the ER. She was admitted and she spent 3 weeks in the hospital, 1 week in ICU. She was eventually diagnosed with the autoimmune disease ANCA Vasculitis. Biopsy confirmed. No previous kidney disease or abnormal blood work. She was treated with high dose steroids and chemotherapy. There was no positive response to treatment. Condition worsened and she was moved to Hospice care. My mother died on 05/16/2021

Administered by: Unknown       Purchased by: ?
Symptoms: Anti-neutrophil cytoplasmic antibody positive vasculitis, Antineutrophil cytoplasmic antibody, Biopsy kidney, Blood bicarbonate, Blood chloride, Blood creatinine, Blood potassium, Blood sodium, Blood urea, Blood urine, Complement factor, Computerised tomogram abdomen, Computerised tomogram pelvis, Diarrhoea, Glucose urine, Immunology test, Laboratory test, Lethargy, Microscopy, Nausea, Nitrite urine, Protein urine, Red blood cells urine, Serology test, Specific gravity urine, Urine albumin/creatinine ratio, Urine analysis, Urine ketone body, Urine leukocyte esterase, Vomiting, White blood cells urine
SMQs:, Acute pancreatitis (broad), Haemorrhage terms (excl laboratory terms) (narrow), Haemorrhage laboratory terms (narrow), Pseudomembranous colitis (broad), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Vasculitis (narrow), Hypersensitivity (narrow), Noninfectious diarrhoea (narrow), Proteinuria (narrow), Hypoglycaemia (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? Yes, ? days
Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Hypertension; Paroxysmal atrial fibrillation; Type 2 diabetes mellitus
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: Test Date: 2021; Test Name: Specific gravity; Result Unstructured Data: Test Result:1.013; Comments: Days Relative to First Vaccine Dose at +16; Test Date: 2021; Test Name: Specific gravity; Result Unstructured Data: Test Result:1.017; Comments: Days Relative to First Vaccine Dose at +28; Test Date: 2021; Test Name: urinary albumin creatinine ratio; Result Unstructured Data: Test Result:2.05; Comments: Random urinary albumin creatinine ratio was 2.05 g/g.; Test Date: 2021; Test Name: urinalysis with blood; Result Unstructured Data: Test Result:(3+); Comments: Routine laboratory assessments obtained 16 days after vaccination were notable; Test Date: 2021; Test Name: Ketones; Test Result: Negative ; Comments: Days Relative to First Vaccine Dose at -21; Test Date: 2021; Test Name: Ketones; Test Result: Negative ; Comments: Days Relative to First Vaccine Dose at +16; Test Date: 2021; Test Name: Ketones; Result Unstructured Data: Test Result:2+; Comments: Days Relative to First Vaccine Dose at +28; Test Date: 2021; Test Name: Leukocyte esterase; Result Unstructured Data: Test Result:Negative; Comments: Days Relative to First Vaccine Dose at -21; Test Date: 2021; Test Name: Leukocyte esterase; Result Unstructured Data: Test Result:Trace; Comments: Days Relative to First Vaccine Dose at +16; Test Date: 2021; Test Name: Leukocyte esterase; Result Unstructured Data: Test Result:Negative; Comments: Days Relative to First Vaccine Dose at +28; Test Date: 2021; Test Name: WBCs per HPF; Result Unstructured Data: Test Result:0; Comments: Days Relative to First Vaccine Dose at -21; Unit: /HPF; Test Date: 2021; Test Name: WBCs per HPF; Result Unstructured Data: Test Result:7; Comments: Days Relative to First Vaccine Dose at +16; Test Date: 2021; Test Name: WBCs per HPF; Result Unstructured Data: Test Result:13; Comments: Days Relative to First Vaccine Dose at +28; Test Date: 2021; Test Name: anti-MPO antibody; Result Unstructured Data: Test Result:1.1; Comments: Unit: AI; elevated; Test Date: 2021; Test Name: Kidney biopsy; Result Unstructured Data: Test Result:crescentic necrotizing glomerulonephritis; Comments: Kidney biopsy revealed crescentic necrotizing glomerulonephritis with moderate interstitial inflammation on light microscopy.; Test Date: 2021; Test Name: Serum bicarbonate; Result Unstructured Data: Test Result:29 mEq/l; Comments: Days Relative to First Vaccine Dose at -21; Test Date: 2021; Test Name: Serum bicarbonate; Result Unstructured Data: Test Result:30 mEq/l; Comments: Days Relative to First Vaccine Dose at +16; Test Date: 2021; Test Name: Serum bicarbonate; Result Unstructured Data: Test Result:26 mEq/l; Comments: Days Relative to First Vaccine Dose at +28; Test Date: 2021; Test Name: Serum chloride; Result Unstructured Data: Test Result:97 mEq/l; Comments: Days Relative to First Vaccine Dose at -21; Test Date: 2021; Test Name: Serum chloride; Result Unstructured Data: Test Result:100 mEq/l; Comments: Days Relative to First Vaccine Dose at +16; Test Date: 2021; Test Name: Serum chloride; Result Unstructured Data: Test Result:97 mEq/l; Comments: Days Relative to First Vaccine Dose at +28; Test Date: 2021; Test Name: Serum creatinine; Test Result: 0.77 mg/dl; Comments: Days Relative to First Vaccine Dose at -21; Routine laboratory assessments obtained a few weeks prior to vaccination were notable for an Scr of 0.77 mg/dL; Test Date: 2021; Test Name: Serum creatinine; Test Result: 1.31 mg/dl; Comments: Days Relative to First Vaccine Dose at +16; Routine laboratory assessments obtained 16 days after vaccination were notable for a serum creatinine level (Scr) of 1.31 mg/dL.; Test Date: 2021; Test Name: Serum creatinine; Test Result: 3.54 mg/dl; Comments: Days Relative to First Vaccine Dose at +28; Test Date: 2021; Test Name: Serum creatinine; Test Result: 2.25 mg/dl; Comments: Her Scr improved to 2.25 mg/dL at the time of discharge; Test Date: 2021; Test Name: Serum creatinine; Test Result: 1.71 mg/dl; Comments: 1.71 mg/dL at the 1 month follow-up.; Test Date: 2021; Test Name: Serum potassium; Result Unstructured Data: Test Result:4.2 mEq/l; Comments: Days Relative to First Vaccine Dose at -21; Test Date: 2021; Test Name: Serum potassium; Result Unstructured Data: Test Result:4.5 mEq/l; Comments: Days Relative to First Vaccine Dose at +16; Test Date: 2021; Test Name: Serum potassium; Result Unstructured Data: Test Result:4.5 mEq/l; Comments: Days Relative to First Vaccine Dose at +28; Test Date: 2021; Test Name: Serum sodium; Result Unstructured Data: Test Result:135 mEq/l; Comments: Days Relative to First Vaccine Dose at -21; Test Date: 2021; Test Name: Serum sodium; Result Unstructured Data: Test Result:136 mEq/l; Comments: Days Relative to First Vaccine Dose at +16; Test Date: 2021; Test Name: Serum sodium; Result Unstructured Data: Test Result:135 mEq/l; Comments: Days Relative to First Vaccine Dose at +28; Test Date: 2021; Test Name: SUN; Test Result: 18 mg/dl; Comments: Days Relative to First Vaccine Dose at -21; Test Date: 2021; Test Name: SUN; Test Result: 22 mg/dl; Comments: Days Relative to First Vaccine Dose at +16; Test Date: 2021; Test Name: SUN; Test Result: 42 mg/dl; Comments: Days Relative to First Vaccine Dose at +28; Test Date: 2021; Test Name: Blood/Urinalysis; Test Result: Negative ; Comments: Days Relative to First Vaccine Dose at -21; Test Date: 2021; Test Name: Blood/Urinalysis; Result Unstructured Data: Test Result:3+; Comments: Days Relative to First Vaccine Dose at +16; Test Date: 2021; Test Name: Blood/Urinalysis; Result Unstructured Data: Test Result:3+; Comments: Days Relative to First Vaccine Dose at +28; Test Date: 2021; Test Name: Complement levels; Result Unstructured Data: Test Result:were unremarkable; Test Date: 2021; Test Name: computed tomography of the abdomen; Result Unstructured Data: Test Result:showed no acute abnormality; Test Date: 2021; Test Name: computed tomography of the pelvis; Result Unstructured Data: Test Result:showed no acute abnormality; Test Date: 2021; Test Name: Glucose; Test Result: Negative ; Comments: Days Relative to First Vaccine Dose at -21; Test Date: 2021; Test Name: Glucose; Test Result: Negative ; Comments: Days Relative to First Vaccine Dose at +16; Test Date: 2021; Test Name: Glucose; Test Result: Negative ; Comments: Days Relative to First Vaccine Dose at +28; Test Date: 2021; Test Name: Immunofluorescence; Result Unstructured Data: Test Result:confirmed pauciimmune glomerulonephritis. She was; Comments: confirmed pauciimmune glomerulonephritis. She was diagnosed with renal-limited MPO-AAV; Test Date: 2021; Test Name: Routine laboratory; Result Unstructured Data: Test Result:assessments obtained 16 days after vaccination wer; Comments: assessments obtained 16 days after vaccination were notable for a serum creatinine level (Scr) of 1.31 mg/dL and urinalysis with blood (3+), 99 red blood cells (RBCs) per high-power field, 7 white blood cells (WBCs) per highpower field, and 100 mg/dL protein; Test Date: 2021; Test Name: Routine laboratory; Result Unstructured Data: Test Result:assessments obtained a few weeks prior to vaccinat; Comments: assessments obtained a few weeks prior to vaccination were notable for an Scr of 0.77 mg/dL and urinalysis with absent hematuria and proteinuria.; Test Date: 2021; Test Name: Routine laboratory; Result Unstructured Data: Test Result:28 days after the first vaccine dose, laboratory a; Comments: 28 days after the first vaccine dose, laboratory assessments were notable for an Scr of 3.54 mg/dL and urinalysis with blood (3+), 56 RBCs per high-power field, 13 WBCs per highpower field, and 100 mg/dL protein; Test Date: 2021; Test Name: urine microscopy; Result Unstructured Data: Test Result:A manual urine microscopy revealed; Comments: A manual urine microscopy revealed 1-2 granular casts per high-power field, few renal tubular epithelial cells, too-numerous-to-count RBCs ($g10% dysmorphic), and few WBCs.; Test Date: 2021; Test Name: Nitrite level; Test Result: Negative ; Comments: Days Relative to First Vaccine Dose at -21; Test Date: 2021; Test Name: Nitrite level; Test Result: Negative ; Comments: Days Relative to First Vaccine Dose at +16; Test Date: 2021; Test Name: Nitrite level; Test Result: Negative ; Comments: Days Relative to First Vaccine Dose at +28; Test Date: 2021; Test Name: Protein; Test Result: Negative ; Comments: Days Relative to First Vaccine Dose at -21; Test Date: 2021; Test Name: Protein; Test Result: 100 mg/dl; Comments: Days Relative to First Vaccine Dose at +16; Test Date: 2021; Test Name: Protein; Test Result: 100 mg/dl; Comments: Days Relative to First Vaccine Dose at +28; Test Date: 2021; Test Name: RBCs per HPF; Result Unstructured Data: Test Result:0; Comments: Days Relative to First Vaccine Dose at -21; unit: /HPF; Test Date: 2021; Test Name: RBCs per HPF; Result Unstructured Data: Test Result:99; Comments: Days Relative to First Vaccine Dose at +16; Test Date: 2021; Test Name: RBCs per HPF; Result Unstructured Data: Test Result:56; Comments: Days Relative to First Vaccine Dose at +28; Test Date: 2021; Test Name: Serologic test; Result Unstructured Data: Test Result:unremarkable; Test Date: 2021; Test Name: Specific gravity; Result Unstructured Data: Test Result:1.021; Comments: Days Relative to First Vaccine Dose at -21
CDC Split Type: USPFIZER INC202101082720

Write-up: ANCA-Associated Vasculitis; nausea; vomiting; diarrhea; lethargy; This is a literature report following Pfizer-BioNTech COVID-19 Vaccine. A 78-year-old woman with a past medical history of type 2 diabetes mellitus, hypertension, and paroxysmal atrial fibrillation received her first dose of the Pfizer-BioNTech COVID-19 vaccine in early February 2021, after which she developed nausea, vomiting, and diarrhea. Routine laboratory assessments obtained 16 days after vaccination were notable for a serum creatinine level (Scr) of 1.31 mg/dL and urinalysis with blood (3+), 99 red blood cells (RBCs) per high-power field, 7 white blood cells (WBCs) per highpower field, and 100 mg/dL protein. Routine laboratory assessments obtained a few weeks prior to vaccination were notable for an Scr of 0.77 mg/dL and urinalysis with absent hematuria and proteinuria. Her symptoms improved spontaneously, and she received the second dose of the Pfizer-BioNTech COVID-19 vaccine 22 days after the first injection. After the second dose, she once again noted symptoms of nausea, vomiting, and diarrhea, as well as new-onset lethargy. At the time of presentation, 28 days after the first vaccine dose, laboratory assessments were notable for an Scr of 3.54 mg/dL and urinalysis with blood (3+), 56 RBCs per high-power field, 13 WBCs per highpower field, and 100 mg/dL protein. The patient had no documented history of COVID-19. She was referred to the emergency department, where computed tomography of the abdomen and pelvis showed no acute abnormality. She was started on intravenous crystalloid, without improvement in Scr, prompting nephrology consult. A manual urine microscopy revealed 1-2 granular casts per high-power field, few renal tubular epithelial cells, too-numerous-to-count RBCs ($g10% dysmorphic), and few WBCs. Random urinary albumincreatinine ratio was 2.05 g/g. The patient was found to have an elevated titer of anti-MPO antibody (titer: 1.1 AI; normal: <0.2 AI). Complement levels and other serologic tests were unremarkable. She was started on intravenous methylprednisolone for 3 days and prednisone 1 mg/kg daily after that. Kidney biopsy revealed crescentic necrotizing glomerulonephritis with moderate interstitial inflammation on light microscopy. Immunofluorescence confirmed pauciimmune glomerulonephritis. She was diagnosed with renal-limited MPO-AAV and she was started on rituximab. Her Scr improved to 2.25 mg/dL at the time of discharge and 1.71 mg/dL at the 1 month follow-up. Other lab tests included Serum bicarbonate (22-32 mEq/l): 29 (Days Relative to First Vaccine Dose at -21), 30 (Days Relative to First Vaccine Dose at +16), 26 (Days Relative to First Vaccine Dose at +28); Serum chloride (98-110 mEq/l): 97 (Days Relative to First Vaccine Dose at -21), 100 (Days Relative to First Vaccine Dose at +16), 97 (Days Relative to First Vaccine Dose at +28); Serum creatinine (0-4.1 mg/dl): 0.77 (First Vaccine Dose at -21; Routine laboratory assessments obtained a few weeks prior to vaccination were notable for an Scr of 0.77 mg/dL), 1.31 (after vaccination were notable for a serum creatinine level (Scr) of 1.31 mg/dL), 3.54 (Days Relative to First Vaccine Dose at +28), 2.25 (Her Scr improved to 2.25 mg/dL at the time of discharge), 1.71 (1.71 mg/dL at the 1 month follow-up), Serum potassium (3.6-5.1 mEq/l): 4.2 (Days Relative to First Vaccine Dose at -21), 4.5 (Days Relative to First Vaccine Dose at +16), 4.5 (Days Relative to First Vaccine Dose at +28); Serum sodium (135-145 mEq/l): 135 (Days Relative to First Vaccine Dose at -21), 136 (Days Relative to First Vaccine Dose at +16), 135 (Days Relative to First Vaccine Dose at +28), SUN (6-24 mg/dl): 18 (Days Relative to First Vaccine Dose at -21), 22 (Days Relative to First Vaccine Dose at +16), 42 (Days Relative to First Vaccine Dose at +28), Blood/Urinalysis: Negative (Days Relative to First Vaccine Dose at -21), 3+ (Days Relative to First Vaccine Dose at +16), 3+ (Days Relative to First Vaccine Dose at +28), Glucose: Negative (Days Relative to First Vaccine Dose at -21), Negative (Days Relative to First Vaccine Dose at +16), Negative (Days Relative to First Vaccine Dose at +28), Nitrite level: Negative (Days Relative to First Vaccine Dose at -21), Negative (Days Relative to First Vaccine Dose at +16), Negative (Days Relative to First Vaccine Dose at +28), Protein (-10 mg/dl): Negative (Days Relative to First Vaccine Dose at -21), 100 (Days Relative to First Vaccine Dose at +16), 100 (Days Relative to First Vaccine Dose at +28), RBCs per HPF (0-5): 0 (Days Relative to First Vaccine Dose at -21; unit: /HPF), 99 (Days Relative to First Vaccine Dose at +16), 56 (Days Relative to First Vaccine Dose at +28), Specific gravity (1.010-1.030): 1.021 (Days Relative to First Vaccine Dose at -21), 1.013 (Days Relative to First Vaccine Dose at +16), 1.017 (Days Relative to First Vaccine Dose at +28), Ketones: Negative (Days Relative to First Vaccine Dose at -21), Negative (Days Relative to First Vaccine Dose at +16), 2+ (Days Relative to First Vaccine Dose at +28), Leukocyte esterase: Negative (Days Relative to First Vaccine Dose at -21), Trace (Days Relative to First Vaccine Dose at +16), Negative (Days Relative to First Vaccine Dose at +28), WBCs per HPF (0-6): 0 (Days Relative to First Vaccine Dose at -21; Unit: /HPF), 7 (Days Relative to First Vaccine Dose at +16), 13 (Days Relative to First Vaccine Dose at +28).; Sender''s Comments: Based on the available information and the strong drug event temporal association, a possible contributory role of suspect product BNT162B2 to development of event Anti-neutrophil cytoplasmic antibody positive vasculitis cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.

Administered by: Public       Purchased by: ?
Symptoms: Anti-neutrophil cytoplasmic antibody positive vasculitis, Blood creatinine increased, Dialysis, Pulmonary haemorrhage, Renal failure
SMQs:, Rhabdomyolysis/myopathy (broad), Acute renal failure (narrow), Haemorrhage terms (excl laboratory terms) (narrow), Retroperitoneal fibrosis (broad), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (broad), Torsade de pointes, shock-associated conditions (broad), Hypovolaemic shock conditions (broad), Toxic-septic shock conditions (broad), Anaphylactic/anaphylactoid shock conditions (broad), Hypoglycaemic and neurogenic shock conditions (broad), Vasculitis (narrow), Chronic kidney disease (narrow), Hypersensitivity (narrow), Tumour lysis syndrome (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? Yes
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit? Yes
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: Creat is 9.
CDC Split Type:

Write-up: The patient developed ANCA-associated vasculitis, and developed kidney failure despite aggressive treatment. He had pulmonary hemorrhage as well. He is now permanently on dialysis as a result of the vaccine.

Administered by: Private       Purchased by: ?
Symptoms: Anti-neutrophil cytoplasmic antibody positive vasculitis, Electromyogram abnormal, Granulomatosis with polyangiitis, Nerve injury, Neuralgic amyotrophy, Sensory loss
SMQs:, Rhabdomyolysis/myopathy (broad), Peripheral neuropathy (narrow), Interstitial lung disease (broad), Guillain-Barre syndrome (broad), Accidents and injuries (narrow), Eosinophilic pneumonia (broad), Vasculitis (narrow), Hypersensitivity (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit? Yes
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Taking Aspirin 81 MG Tablet Chewable 1 tablet Orally Once a day, Taking Metoprolol 50 mg 50 MG Tablet Extended Release Orally , Taking Amlodipine 5 mg 1 Tablet Orally Once a day, Taking Co Q 10 200 MG Capsule 1 capsule with a meal Orally On
Current Illness:
Preexisting Conditions: CAD (coronary artery disease) of native coronary artery without angina pectoris ... Essential (primary) hypertension ... Hypothyroidism ... Essential (primary) hypertension ... Hyperlipemia ... GERD (gastroesophageal reflux disease) ... Aortic stenosis ...
Allergies: none
Diagnostic Lab Data: abnl EMG 10/19/21: PR3-ANCA positive Parsonage Turner syndrome of the right arm. Onset June ''21, approximately 4 months following her second Pfizer COVID-19 vaccine. This complication is being documented in the literature. Involvement is mostly hand intrinsics, medial cord of the brachial plexus. She is s/p induction therapy with combination of IV steroids and reduced-dose 22 week prednisone taper (on file in EMR) with Rituxan. Symptoms have reached a plateau. Discussed this is goal of treatment, stop the progression and allow a state where healing can take place. Recovery 6-12 months. lab PR3-ANCA positive vasculitis presenting as isolated nerve damage to the right brachial plexus.
CDC Split Type:

Write-up: 1/26/21, 2/23/21 vaccine dates. second lot number is not 100% clearly written so may be incorrect. 1/5 power in finger extension and abduction. 4-/5 in finger adduction and flexion. Wrist extension 4/5 while wrist flexion is normal. Elbow flexion normal with 4/5 in extension. MSR are muted in the arm. Decreased tactile sensation in the hand and along medial aspect of the forearm. PR3-ANCA positive vasculitis presenting as isolated nerve damage to the right brachial plexus. 1. Wegeners granulomatosis Start riTUXimab Solution, 500 MG/50ML, 1 gm, repeat in 14d then 500mg q 6 mos x 3, Intravenous, 7/2021-7/2023, Notes: 30 mins prior to treatment: solumedrol 125mg IV, Tylenol 1g PO, Benadryl 50mg PO Start methylPREDNISolone Sodium Succ Solution Reconstituted, 1000 MG, 1 gm, Injection, x 3d Start predniSONE Tablet, 5 MG, 1-2 tabs as directed per taper schedule, Orally, daily, remain on 5mg daily x 4 wks once tapered to that dose, 30 day(s), 60, Refills 5 Start predniSONE Tablet, 10 MG, 1-3 tabs per taper schedule given to patient, Orally, Once a day, 30 day(s), 90, Refills 5

Administered by: Private       Purchased by: ?
Symptoms: Acute kidney injury, Anti-neutrophil cytoplasmic antibody positive vasculitis, Antineutrophil cytoplasmic antibody positive, Blood creatinine increased, Blood phosphorus, Metabolic function test
SMQs:, Rhabdomyolysis/myopathy (broad), Acute renal failure (narrow), Retroperitoneal fibrosis (broad), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (broad), Torsade de pointes, shock-associated conditions (broad), Hypovolaemic shock conditions (broad), Toxic-septic shock conditions (broad), Anaphylactic/anaphylactoid shock conditions (broad), Hypoglycaemic and neurogenic shock conditions (broad), Vasculitis (narrow), Chronic kidney disease (broad), Hypersensitivity (narrow), Tumour lysis syndrome (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Dehydration (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? Yes
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 7 days
Extended hospital stay? No
Previous Vaccinations:
Other Medications: Patient was being released from the hospital for double pneumonia and received IV antibiotics during the stay.
Current Illness: pneumonia
Preexisting Conditions: memory loss,
Allergies: sulfa, morphine
Diagnostic Lab Data: Basic Metabolic: daily 12/6-12/13 (ongoing) Phosphorus (daily) 12/6-12/13 (on going) Myeloperoxidase Antibody- positive Anca Vasculitis Patient is still in the hospital
CDC Split Type:

Write-up: Anca Vasculitis, acute kidney failure. Patient had no previous kidney issues, normal creatine levels prior to being given the Covid booster. Patient went to her family care physician following release from hospital for routine lab work. Lab work showed Creatine of 6.4 and acute kidney failure. Patient went to the ER and was admitted into the hospital.

Administered by: Other       Purchased by: ?
Symptoms: Angiotensin converting enzyme, Anti-cyclic citrullinated peptide antibody, Anti-neutrophil cytoplasmic antibody positive vasculitis, Antibody test, Antinuclear antibody, Blood 25-hydroxycholecalciferol, Blood calcium, Blood creatine phosphokinase, Blood parathyroid hormone, Blood phosphorus, Blood test, Blood thyroid stimulating hormone, Blood uric acid, C-reactive protein, Complement factor C3, Complement factor C4, Digestive enzyme test, Fatigue, HLA-B*27 assay, Muscular weakness, Musculoskeletal stiffness, Myoglobin blood, Red blood cell sedimentation rate, Rheumatoid factor, X-ray
SMQs:, Rhabdomyolysis/myopathy (broad), Peripheral neuropathy (broad), Dystonia (broad), Parkinson-like events (broad), Guillain-Barre syndrome (broad), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (broad), Vasculitis (narrow), Hypersensitivity (narrow), Arthritis (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? Yes
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Timoptic eye drops, Alphagan eye drops, Lisinopril, Hydrochlorithiazide, Celexa, fish oil, multi vitamen, 81 mg. aspirin, voltaren
Current Illness: none
Preexisting Conditions: high blood pressure, glaucoma
Allergies: Morphine
Diagnostic Lab Data: 1-21-22 multiple blood tests and x-rays. CK, ADOLASE WARDE, MYOGLOBIN, C-REACTIVE PROTEIN, SED RATE, ANTI CCP, ANA, URIC ACID, RHEUMATOID FACTOR, HLAB27, ANGIOTENSIN, ANTINEUTROPHILIC CYTOPLASMIC AB RF, SSA AND SSB AB IGG, C3COMPLEMENT, C4 COMPLEMENT, VITAMEN D 25 HYDROXY, CALCIUM, PHOSPHORUS, TSH, PTH INTACT W/O CA
CDC Split Type:

Write-up: severe stiffness in back, upper shoulders, neck and legs, weekness in thighs, fatigue. given a course of Steroids for stiffness which improved symptoms. Saw a rheumatologist and after blood work determined to have ANCA positive vasculitis. will repeat blood tests to see if it improves.

Administered by: Pharmacy       Purchased by: ?
Symptoms: Anti-neutrophil cytoplasmic antibody positive vasculitis, Appendicitis, Autoimmune disorder, Biopsy kidney, Blood urine present, Computerised tomogram, Cystoscopy, Endoscopy, Laboratory test, Protein urine present, Pulmonary embolism, Renal disorder
SMQs:, Acute renal failure (broad), Haemorrhage terms (excl laboratory terms) (narrow), Haemorrhage laboratory terms (narrow), Systemic lupus erythematosus (broad), Embolic and thrombotic events, venous (narrow), Vasculitis (narrow), Chronic kidney disease (broad), Hypersensitivity (narrow), Proteinuria (narrow), Tubulointerstitial diseases (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? Yes
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? Yes, 5 days
Extended hospital stay? No
Previous Vaccinations:
Other Medications: procardia 30 mg
Current Illness: NA
Preexisting Conditions: aortic aneurysm repair 2006
Allergies: cozaar
Diagnostic Lab Data: Numerous labs Endoscope Cystoscope kidney biopsy prednisone rituximab infusions CT scans
CDC Split Type:

Write-up: autoimmune disease p-anca vasculitis Pulmonary Embolisms Appendicitis Kidney Disease Blood/protein in urine

Administered by: Private       Purchased by: ?
Symptoms: Acute kidney injury, Anti-neutrophil cytoplasmic antibody positive vasculitis, Antineutrophil cytoplasmic antibody, Antinuclear antibody, Biopsy kidney, Blood creatinine increased, Complement factor C3, Complement factor C4, Double stranded DNA antibody, Full blood count, Haematuria, IgA nephropathy, Metabolic function test, Ultrasound kidney, Urine abnormality, Urine analysis, Urine protein/creatinine ratio
SMQs:, Rhabdomyolysis/myopathy (broad), Acute renal failure (narrow), Haemorrhage terms (excl laboratory terms) (narrow), Systemic lupus erythematosus (broad), Retroperitoneal fibrosis (broad), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (broad), Torsade de pointes, shock-associated conditions (broad), Hypovolaemic shock conditions (broad), Toxic-septic shock conditions (broad), Anaphylactic/anaphylactoid shock conditions (broad), Hypoglycaemic and neurogenic shock conditions (broad), Vasculitis (narrow), Chronic kidney disease (broad), Hypersensitivity (narrow), Tumour lysis syndrome (broad), Proteinuria (broad), Tubulointerstitial diseases (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Dehydration (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? Yes
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? Yes
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 8 days
Extended hospital stay? No
Previous Vaccinations:
Other Medications: Clonidine 0.2 mg at night, methylphenidate 18 mg
Current Illness: none reported per patient.
Preexisting Conditions: ADHD, tourette''s
Allergies: none
Diagnostic Lab Data: In patient hospitalization, kidney biopsy, kidney ultrasound, CBC, CMP, ANCA levels (MPO/PR3), ANA, dsDNA, C3/C4, UA, Urine protein/creatinine, 24hr urine. (5/15 - 5/23/22)
CDC Split Type:

Write-up: Pt developed hematuria and foaminess in urine 4-5 days after second Pfizer vaccine. Was admitted to hospital on 5/15 with AKI Cr 3s, underwent kidney biopsy showing MPO+ ANCA vasculitis with background IgA nephropathy. Started on pulse steroids and Rituximab with improvement of kidney function. Creatinine had peaked to 4 now improving to 3.